Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00187525
Status:
COMPLETED
Last Update Posted:
2012-11-12
First Post:
2005-09-13
Brief Title:
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 52-week multicenter open label trial of memantine Namenda for frontotemporal lobar degeneration FTLD The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimers Disease in patients with FTLD Secondary outcome measures include cognitive batteries rating scales for activities of daily living and neuropsychiatric symptoms All patients receive the FDA-approved dose of this medication for Alzheimers disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None